PLoS ONE 2015-01-01

Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.

Fernando G Vieira, Qinggong Ping, Andy J Moreno, Joshua D Kidd, Kenneth Thompson, Bingbing Jiang, John M Lincecum, Monica Z Wang, Gerard S De Zutter, Valerie R Tassinari, Beth Levine, Theo Hatzipetros, Alan Gill, Steven Perrin

Index: PLoS ONE 10 , e0135570, (2015)

Full Text: HTML

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons. The mechanisms leading to motor neuron degeneration in ALS are unclear. However, there is evidence for involvement of endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) in ALS, notably in mutant SOD1 mediated models of ALS. Stress induced phosphorylation of the eIF2 alpha subunit by eukaryotic translation initiation factor 2-alpha kinase 3 Perk activates the UPR. Guanabenz is a centrally acting alpha2 adrenergic receptor agonist shown to interact with a regulatory subunit of the protein phosphatase, Pp1/Gadd34, and selectively disrupt the dephosphorylation of the alpha subunit of eukaryotic initiation factor 2 (eif2alpha). Here we demonstrate that guanabenz is protective in fibroblasts expressing G93A mutant SOD1 when they are exposed to tunicamycin mediated ER stress. However, in contrast to other reports, guanabenz treatment accelerated ALS-like disease progression in a strain of mutant SOD1 transgenic ALS mice. This study highlights challenges of pharmacological interventions of cellular stress responses in whole animal models of ALS.